Alpha 2.0
Login Register
» Authors » Jane Hanson

Jane Hanson

Explore the profile of Jane Hanson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 1041
Followers 0
Related Specialties
Oncology
Public Health
Health Services
Top 10 Co-Authors
Iain J Robbe
Anita Ashton
Richard D Neal
Janis Homewood
John Yarnold
Caroline Harper
Wenli Geng
Anna McGlothlin
Christelle Aparicio
Shaman Jhanji
Published In
Radiother Oncol
BMC Cancer
Lancet Oncol
Prim Health Care Res Dev
Health Policy
Affiliations
Soon will be listed here.
Recent Articles
1.
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
Angus D, Buzgau A, Cheng A, Higgins A, Hullegie S, Lawler P, et al.
JAMA . 2020 Sep; 324(13):1317-1329. PMID: 32876697
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, And Participants: An...
2.
The complexity and difficulty of diagnosing lung cancer: findings from a national primary-care study in Wales
Neal R, Robbe I, Lewis M, Williamson I, Hanson J
Prim Health Care Res Dev . 2014 Dec; 16(5):436-49. PMID: 25482333
Aim: This paper aims to provide a detailed analysis of the diagnostic process of lung cancer from a primary-care perspective. Background: Diagnosing lung cancer at a stage where curative treatment...
3.
Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample
Brain K, Smits S, Simon A, Forbes L, Roberts C, Robbe I, et al.
BMC Cancer . 2014 Mar; 14:171. PMID: 24612526
Background: While ovarian cancer is recognised as having identifiable early symptoms, understanding of the key determinants of symptom awareness and early presentation is limited. A population-based survey of ovarian cancer...
4.
The International Cancer Benchmarking Partnership: an international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom
Butler J, Foot C, Bomb M, Hiom S, Coleman M, Bryant H, et al.
Health Policy . 2013 May; 112(1-2):148-55. PMID: 23693117
The International Cancer Benchmarking Partnership (ICBP) was initiated by the Department of Health in England to study international variation in cancer survival, and to inform policy to improve cancer survival....
5.
Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy
Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, et al.
Radiother Oncol . 2007 Jan; 82(3):254-64. PMID: 17224195
Background: Radiation dose distributions created by two dimensional (2D) treatment planning are responsible for partial volumes receiving >107% of the prescribed dose in a proportion of patients prescribed whole breast...
6.
Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial
Owen J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al.
Lancet Oncol . 2006 Jun; 7(6):467-71. PMID: 16750496
Background: Standard curative schedules of radiotherapy to the breast deliver 25 fractions of 2.0 Gy over 5 weeks. In a randomised trial, we tested whether fewer, larger fractions were at...
7.
Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial
Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al.
Radiother Oncol . 2005 May; 75(1):9-17. PMID: 15878095
Background And Purpose: Unlike squamous carcinomas, breast adenocarcinoma may be as sensitive to fraction size as late dose-limiting normal tissues. If so, fewer larger fractions would be as safe and...